Literature DB >> 25928572

Effect of the beta-3 adrenergic receptor Trp64Arg and uncoupling protein 1-3826 A>G genotypes on lipid and apolipoprotein levels in overweight/obese and non-obese Chinese subjects.

Yihong Chen1, Xiaosu Wang2, Zheni Shen3, Ping Fan4, Rui Liu5, Yu Liu6, Rongmei Ren7, Lei Ma8, Huai Bai9.   

Abstract

BACKGROUND: The beta-3 adrenergic receptor (β3-AR) Trp64Arg and uncoupling protein 1 (UCP1) -3826 A>G polymorphisms have been reported to be associated with obesity and/or lipid metabolism in some populations. This study examined the possible association of the β3-AR and UCP1 polymorphisms with overweight/obesity or lipid variation in a Southwest Chinese population.
METHODS: A total of 418 Han Chinese (249 overweight/obese and 169 healthy control subjects) in the Chengdu area were studied using PCR-RFLP analysis. Total serum cholesterol (TC) and triglycerides (TGs) were measured using an enzymatic method. High density lipoprotein cholesterol (HDL-C) was determined after sodium phosphotungstate/magnesium chloride precipitation of low-density lipoproteins by polyvinyl sulfate. Serum apolipoproteins were quantified by radial immunodiffusion.
RESULTS: The genotype and allele frequencies of the β3-AR Trp64Arg and UCP1 -3826 A>G polymorphisms in overweight/obese subjects exhibited no significant differences compared to the controls. However, subjects carrying the β3-AR TrpTrp genotype and UCP1 AG genotype had higher TG levels than those carrying the Arg allele and AA genotype, respectively (P<0.05), while controls carrying the β3-AR Arg allele had significantly higher TC and apo AII concentrations than those carrying the TrpTrp genotype (P<0.05). Additionally, subjects carrying the UCP1 AG genotype exhibited elevated apo C-II and apo C-III levels compared to those carrying the AA genotype (P<0.05). We were unable to find an association of the UCP1 and β3-AR polymorphisms with low HDL-cholesterolemia in the overweight/obese subjects.
CONCLUSIONS: The present study provides evidence that the β3-AR Trp64Arg and UCP1 -3826 A>G polymorphisms are associated with TG levels in overweight/obese Chinese subjects and that the two polymorphisms are also associated with certain lipid and apolipoprotein variations, depending on BMI. However, these polymorphisms are not associated with overweight/obesity or low HDL-cholesterolemia in a Chinese population from the Chengdu area.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25928572      PMCID: PMC4410578          DOI: 10.1186/s12944-015-0029-y

Source DB:  PubMed          Journal:  Lipids Health Dis        ISSN: 1476-511X            Impact factor:   3.876


Background

Obesity is strongly associated with an adverse dyslipidemic profile and increased risks for diabetes, hypertension, and coronary artery disease. Although this relationship has been described in detail, its pathophysiological basis remains unclear. Studies have suggested that obesity is linked to genetic and environmental factors and that most obesity-predisposing genes encode the molecular components of the physiological systems regulating energy balance [1]. The β3-AR gene has been established as the principal mediator of thermogenesis in brown adipose tissue and lipolysis in white adipose tissue both in animals and humans [2-4]. A β3-AR Trp64Arg polymorphism decreases receptor sensitivity [5,6] and may be associated with obesity and related traits [5,7,8]. The human uncoupling protein-1, which is expressed in brown adipose tissue, dissipates the transmitochondrial proton gradient as heat and plays an important role in energy homeostasis and thermogenesis [9,10]. UCP1 gene polymorphisms have been implicated in the pathogenesis of obesity and related metabolic disorders, including lipid disorders [11,12]. A −3826 A > G polymorphism within the promoter region of the UCP-1 gene is a candidate gene polymorphic site related to these disorders [13-15]. Additionally, several studies have also suggested that the UCP1 -3826 A > G and β3-AR Trp64Arg polymorphisms are related to low HDL-cholesterolemia and HDL-cholesterol levels in some populations [16-20]. However, the results of these studies were not confirmed in other studies [21-26]. Furthermore, no data concerning the relationships between the β3-AR Trp64Arg and UCP1 -3826A > G polymorphisms and overweight/obesity and lipid profiles have been reported for a Southwest Chinese population. Therefore, we undertook this population-based study to assess whether the β3-AR Trp64Arg and UCP1 -3826 A > G polymorphisms were related to overweight/obesity and lipid profiles in a Southwest Chinese population.

Results

Baseline characteristics of the participants in the population

The lipid and lipoprotein profiles for both the overweight/obese and control groups are provided in Table 1. The serum TG, apo CII, apo C-III and apoE levels were significantly higher and the HDL-C was significantly lower in the overweight/obese group compared to the control group (P < 0.05 or P < 0.01).
Table 1

Clinical and biochemical characteristics of the overweight/obese and control subjects ( )

Overweight/obese (n = 249) Controls (n = 169) P
Age (yrs)55.04 ± 10.0053.35 ± 11.780.115
Gender (M/F)149/10093/760.322
TG (mmol/L)2.31 ± 1.701.72 ± 1.560.000
TC (mmol/L)5.43 ± 0.925.41 ± 1.110.788
HDL-C (mmol/L)1.17 ± 0.321.41 ± 0.410.000
LDL-C (mmol/L) a3.29 ± 0.87 b3.26 ± 1.040.821
apoA-I (mg/dL)124.20 ± 27.96128.97 ± 23.890.077
apoA-II (mg/dL)28.39 ± 4.5829.07 ± 6.920.227
apoB100 (mg/dL)88.93 ± 17.0684.04 ± 20.930.427
apoC-II (mg/dL)6.68 ± 3.325.61 ± 3.100.001
apoC-III (mg/dL)17.47 ± 7.0313.09 ± 6.170.000
Apo E (mg/dL)5.27 ± 1.964.87 ± 2.260.043
BMI (kg/m2)25.72 ± 2.2520.74 ± 1.600.000

Subjects with TG > 4.516 mmol/L (400 mg/dL) were excluded when calculating the serum LDL-C levels, a: n = 193, b: n = 145.

Clinical and biochemical characteristics of the overweight/obese and control subjects ( ) Subjects with TG > 4.516 mmol/L (400 mg/dL) were excluded when calculating the serum LDL-C levels, a: n = 193, b: n = 145.

Allele frequencies

The PCR amplified fragments (containing the 3-AR Trp64Arg and UCP1 -3826 A > G polymorphic sites) from each sample were digested with the restriction enzyme Bst NI for the Trp64Arg site and Bcl I for the −3826 A > G site; then, the digested fragments were analysed by agarose gel electrophoresis. Genotypes of the Trp64Arg and −3826 A > G polymorphisms were found to be in Hardy-Weinberg equilibrium in both the overweight/obese and control groups. The frequency data are presented in Table 2.
Table 2

Genotype and allele frequencies of the β Thr64Arg and -3826 A > G polymorphisms in the overweight/obese and control groups

Frequencies
Overweight/Obese (n = 249) Controls (n = 169) P
β3-AR Trp64Arg Genotype0.414
  Trp Trp0.739 (184)0.734 (124)
  Trp Arg0.253 (63)0.243 (41)
  Arg Arg0.008 (2)0.024 (4)
  Allele0.668
  Trp0.865 (431)0.855 (289)
  Arg0.135 (67)0.145 (49)
UCP1 -3826 A/G Genotype0.824
  AA0.249 (62)0.225 (38)
  AG0.454 (113)0.479 (81)
  GG0.297 (74)0.296 (50)
  Allele0.746
  A0.476 (237)0.464 (157)
  G0.524 (261)0.536 (181)

Numbers in parentheses indicate the number of subjects with each genotype or number of alleles of each type.

Genotype and allele frequencies of the β Thr64Arg and -3826 A > G polymorphisms in the overweight/obese and control groups Numbers in parentheses indicate the number of subjects with each genotype or number of alleles of each type. The Trp and Arg allele frequencies of the β3-AR gene at codon 64 in the overweight/obese and normal control groups were 0.865, 0.135 and 0.855, 0.145, respectively, while the A and G allele frequencies at the −3826 A > G site of the UCP1 gene were 0.476, 0.524 and 0.464, 0.536, respectively. The allele frequencies of the two polymorphisms in the overweight/obese subjects were not different from those in the controls (P > 0.05). Moreover, no significant difference in genotype frequencies was observed when the genotypes were divided into two categories according to the dominant model or recessive model at the β3-AR Trp64Arg and UCP1 -3826 A > G sites (all P > 0.05). Multiple logistic regression analysis was used to assess the association of the β3-AR Trp64Arg and UCP1 -3826 A > G polymorphisms with overweight/obesity. Assuming a dominant or recessive inheritance model, no association of the two polymorphisms were found after adjusting for age and sex (all P > 0.05).

Effects of polymorphic sites of the β3-AR and UCP1 genes on serum concentrations of lipids and apolipoproteins

To assess the possible impact of the polymorphic sites in the β3-AR and UCP1 genes on lipid metabolism, we analysed serum lipid and lipoprotein levels in subjects possessing the different genotypes of the Trp64Arg and −3826 A > G polymorphisms in both the overweight/obese and normal control groups. In the overweight/obese group, subjects with the TrpTrp genotype at the Trp64Arg site of the β3-AR gene had higher serum TG concentrations than the Arg allele carriers (TG: 2.40 ± 1.79 mmol/L vs 1.95 ± 1.11 mmol/L, P < 0.05) (Table 3), while in the normal controls the Arg allele carriers had higher TC and apoA-II concentrations than the TrpTrp genotype carriers (all P < 0.05) (Table 3).
Table 3

Mean values of serum lipid and apolipoprotein levels for the Thr64 Arg site of the gene in the overweight/obese and control groups

Overweight/obese Controls
TrpTrp (n = 184) Trp Arg + ArgArg (n = 65) TrpTrp (n = 124) TrpArg + ArgArg (n = 45)
TG (mmol/L)2.40 ± 1.791.95 ± 1.11a,* 1.64 ± 1.052.05 ± 1.54
TC (mmol/L)5.58 ± 1.025.33 ± 0.775.36 ± 1.045.77 ± 1.42b,*
HDL-C (mmol/L)1.16 ± 0.311.24 ± 0.361.41 ± 0.411.44 ± 0.42
LDL-C (mmol/L) d3.32 ± 0.91 e3.19 ± 0.73 f3.21 ± 1.01 g3.42 ± 1.15
apoA-I (mg/dL)125.21 ± 29.49124.33 ± 21.42130.21 ± 22.58126.13 ± 27.23
apoA-II (mg/dL)28.54 ± 4.7528.48 ± 4.9028.53 ± 4.2131.26 ± 11.61c,*
apoB100 (mg/dL)93.44 ± 20.7486.50 ± 14.4189.38 ± 21.2783.70 ± 23.98
apoC-II (mg/dL)6.88 ± 3.506.12 ± 2.645.52 ± 2.955.99 ± 3.69
apoC-III (mg/dL)15.92 ± 7.5314.21 ± 4.7913.04 ± 5.6913.76 ± 7.67
Apo E (mg/dL)5.39 ± 2.114.95 ± 1.424.75 ± 1.785.35 ± 3.29

abcCompared with genotype TrpTrp carriers in the same group, respectively, *P < 0.05.

Subjects with TG > 4.516 mmol/L (400 mg/dL) were excluded when calculating the serum LDL-C levels, d: n = 142, e: n = 51, f: n = 108, g: n = 37.

∆Age and sex were used as covariates in the analysis to adjust for the genotype effects.

Mean values of serum lipid and apolipoprotein levels for the Thr64 Arg site of the gene in the overweight/obese and control groups abcCompared with genotype TrpTrp carriers in the same group, respectively, *P < 0.05. Subjects with TG > 4.516 mmol/L (400 mg/dL) were excluded when calculating the serum LDL-C levels, d: n = 142, e: n = 51, f: n = 108, g: n = 37. ∆Age and sex were used as covariates in the analysis to adjust for the genotype effects. In the overweight/obese group, subjects with the AG genotype of the A > G polymorphism of the UCP1 gene had a higher serum mean concentration of TG, apo C-II and apo C-III compared to patients with the AA genotype (Table 4; all P < 0.05). No significant effect on lipid and apolipoprotein levels was observed for the UCP1 -3826 A > G polymorphism in the normal control subjects.
Table 4

Mean values ( ) of serum lipid and apolipoprotein levels for the −3826 A > G site of the gene in the overweight/obese and control groups

Overweight/Obese Controls
AA (n = 62) AG (n = 119) GG (n = 74) AA (n = 38) AG (n = 83) GG (n = 53)
TG (mmol/L)1.92 ± 1.212.53 ± 1.94a,* 2.23 ± 1.501.58 ± 0.831.64 ± 1.191.88 ± 2.25
TC (mmol/L)5.28 ± 1.005.43 ± 0.865.58 ± 0.905.39 ± 1.175.41 ± 1.035.38 ± 1.19
HDL-C (mmol/L)1.20 ± 0.291.17 ± 0.331.17 ± 0.311.44 ± 0.511.43 ± 2.341.38 ± 0.41
LDL-C (mmol/L) d3.16 ± 0.97 e3.24 ± 0.81 f3.44 ± 0.87 g3.20 ± 1.21 h3.21 ± 1.01 i3.19 ± 0.98
apoA-I (mg/dL)126.06 ± 21.68125.33 ± 34.42120.59 ± 18.45125.77 ± 25.14130.36 ± 23.34128.83 ± 24.14
apoA-II (mg/dL)28.89 ± 4.4928.38 ± 4.7927.98 ± 4.3528.52 ± 4.6228.87 ± 8.8229.71 ± 4.12
apoB100 (mg/dL)100.15 ± 113.5188.99 ± 17.1391.14 ± 16.6788.08 ± 25.7491.23 ± 88.7781.35 ± 19.56
ApoC-II (mg/dL)5.81 ± 2.637.22 ± 3.66b,* 6.58 ± 2.915.31 ± 2.915.61 ± 2.815.73 ± 3.59
ApoC-III (mg/dL)13.99 ± 6.7516.30 ± 7.25c,* 15.24 ± 6.2912.53 ± 5.2313.04 ± 5.6013.22 ± 7.52
Apo E (mg/dL)4.93 ± 1.775.47 ± 2.075.18 ± 1.804.55 ± 1.544.89 ± 1.894.95 ± 3.08

abcCompared with AA genotype carriers in the same group, respectively, *p < 0.05;

Subjects with TG > 4.516 mmol/L (400 mg/dL) were excluded when calculating the serum LDL-C levels, d: n = 43, e: n = 90, f: n = 60, g: n = 34, h: n = 71, i: n = 40.

∆Age and sex were used as covariates in the analysis to adjust for the genotype effects.

Mean values ( ) of serum lipid and apolipoprotein levels for the −3826 A > G site of the gene in the overweight/obese and control groups abcCompared with AA genotype carriers in the same group, respectively, *p < 0.05; Subjects with TG > 4.516 mmol/L (400 mg/dL) were excluded when calculating the serum LDL-C levels, d: n = 43, e: n = 90, f: n = 60, g: n = 34, h: n = 71, i: n = 40. ∆Age and sex were used as covariates in the analysis to adjust for the genotype effects.

Evaluation of the relationship between polymorphic sites in the β3-AR and UCP1 genes and low HDL-cholesterolemia

Previous studies have suggested that the UCP1 -3826 A > G polymorphism was related to low HDL-cholesterolemia and low HDL-cholesterol levels in some populations with obesity. Additionally, the β3-AR Trp64Arg polymorphism has been shown to be related to low HDL-cholesterol levels in some ethnic groups. Therefore, we analysed the relationship between polymorphic sites in the β3-AR and UCP1 genes and low cholesterolemia in our population. In the overweight/obese subjects, the allele frequencies of the two polymorphisms in subjects with HDL-C < 1.04 mmol/L were not different from those with HDL-C ≥ 1.04 mmol/L (Table 5, both P > 0.05).
Table 5

Genotype and allele frequencies of the β Trp64Arg and -3826 A > G polymorphisms according to HDL-C levels in the overweight/obese subjects

Frequencies
HDL-C < 1.04 (n = 101) HDL-C ≥ 1.04 (n = 148) P
β3-AR Trp64Arg Genotype0.893a
  Trp Trp0.762 (77)0.743 (110)
  Trp Arg0.228 (23)0.250 (37)
  Arg Arg0.010 (1)0.007 (1)
 Allele0.794
  Trp1.752 (177)1.736 (257)
  Arg0.248 (25)0.264 (39)
UCP1 -3826 A > G Genotype0.243b
  AA0.198 (20)0.291 (43)
  AG0.485 (49)0.446 (66)
  GG0.317 (32)0.264 (39)
  Allele0.110
  A0.881 (89)1.027 (152)
  G1.119 (113)0.973 (144)

Numbers in parentheses indicate the number of subjects with each genotype or number of alleles of each type.

aArgArg + TrpArg vs. TrpTrp, χ 2 = 1.118, odds radio (ArgArg + TrpArg/TrpTrp) = 0.902, 95% confidence interval 0.501-1.625.

bGG vs. AA + AG, χ 2 = 0.837, odds radio (GG/AA + AG) =1.296, 95% confidence interval 0.743-2.261.

Genotype and allele frequencies of the β Trp64Arg and -3826 A > G polymorphisms according to HDL-C levels in the overweight/obese subjects Numbers in parentheses indicate the number of subjects with each genotype or number of alleles of each type. aArgArg + TrpArg vs. TrpTrp, χ 2 = 1.118, odds radio (ArgArg + TrpArg/TrpTrp) = 0.902, 95% confidence interval 0.501-1.625. bGG vs. AA + AG, χ 2 = 0.837, odds radio (GG/AA + AG) =1.296, 95% confidence interval 0.743-2.261.

Discussion

Our results in the Chinese cohort living in Southwest China showed that both the polymorphisms in the β3-AR and UCP1 genes were associated with TG concentrations in overweight/obese subjects and that the two polymorphisms were also associated with some lipid and apolipoprotein levels (i.e., TC, apoAII, apo CII and apo CIII levels) depending on BMI. However, we did not find an association between the polymorphisms and overweight/obesity or low HDL-cholesterolemia in overweight/obese subjects. These results provide support for the notion that β3-AR and UCP1 are involved in the pathophysiology of metabolic disorders. A total of 423 SNPs in β3-AR and 460 SNPs in UCP1 in both the coding and non-coding regions are available in the public database. Although to date the function of a substantial number of the SNPs in the genes has not been defined, those linked to protein coding substitutions and in the introns, 5’ and 3’ UTRs related to the regulation of gene expression are of potential functional relevance. Among these SNPs, the most widely studied are the β3-AR Trp64Arg and UCP1 -3826 A > G due to their functional importance. There have been many studies concerning the relationship between the Trp64Arg polymorphism of the β3-AR gene and obesity or related phenotypes; however, the results are inconsistent. Clement et al. [5] reported that Arg64 resulted in an increased tendency to accumulate weight in French subjects and that this polymorphism was also associated with obesity [8], difficulty in weight loss and a lower basal metabolic rate [27] in Japanese subjects. In contrast, Ghosh et al. [28] reported that the β3-AR polymorphism was not associated with obesity in a large Finnish sample population, and Shiwaku et al. also did not find an association with moderately overweight Japanese workers [29]. Our results are in line with the reports of Ghosh et al. and Shiwaku et al. The discrepancy among these studies may be caused by several factors, including environmental and genetic factors. With respect to the effect of the β3-AR Trp64Arg polymorphism on lipids and apolipoproteins, Kim-Motoyama et al. [20] reported that the polymorphism was associated with obesity and decreased serum TG levels. Our results in overweight/obese Chinese are in line with the report. A previous report suggested that subjects with this mutation may be characterized by decreased lipolysis in visceral adipose tissues [20]. In the current study, we also found that the Arg allele carriers showed increased TC and apo AII concentrations compared to Trp allele carriers in the normal control subjects, which is in general consistent with the notion that the β3-AR polymorphism is associated with cholesterol metabolism, including a variation of HDL-C components such as apoA-II. We were unable to find a significant association between the polymorphism and HDL-C levels in our population, although reports have suggested that the Arg64 allele carriers of the β3-AR gene had decreased HDL-C levels in some populations [19,20]. There are several reports available concerning the effect of the UCP1 -3826A > G polymorphism on obesity or plasma metabolic parameters. However, controversy remains because some reports do not support this role. For instance, Urhammer et al. [30] showed that the UCP1 polymorphism was not associated with obesity in a Danish population, and Pihlajamaki et al. [31] reported that BMI and serum biochemistry were not significantly different based on UCP1 genotype in Finnish subjects with family combined hyperlipidemia. Schaffler et al. [26] showed that the G allele of UCP1 was not associated with obesity and metabolic parameters in a large sample of German subjects. The current study is supportive of the results from the Danish, Finnish and German populations. Interestingly, we found that TG, apoC-II and apoC-III levels in overweight/obese subjects were elevated in AG genotype carriers compared with AA genotype carriers, suggesting a link between impaired metabolic levels in overweight/obese subjects and this polymorphism. Kotani et al. reported that the UCP1 -3826A > G polymorphism was associated with low HDL-cholesterolemia in obese Japanese patients [32]. In the current study we are unable to find a similar effect in overweight/obese subjects (OR = 1.296, CI = 0.743-2.261, P = 0.360), suggesting that UCP1 gene variation might not predispose overweight/obese Chinese subjects to the development of low HDL-cholesterolemia. Our result is in line with the reports in German Caucasians [26] and young Japanese males [33]. Interestingly, we found that other gene polymorphisms, such as ABCA1 R219K, were associated with low HDL-cholesterolemia in our overweight/obese subjects (n = 206, OR = 2.243, CI = 1.232-4.083, P = 0.008) (data not shown), suggesting that genetic variant(s) other than UCP1 might predispose Chinese populations to low HDL-cholesterolemia. Although the patient and control subjects participating in this study were randomized at enrollment into the respective overweight/obese and control groups, both groups had similar socioeconomic statuses (i.e., salary and education) and background environmental factors (i.e., diet and place of residence), and we attempted to control for some potential confounding factors such as age and sex in the data analyses, there might still have been some degree of uncontrolled confounding factors (i.e., smoking and forms of exercise). Future studies that examine whether any of these confounding factors additionally acted as effect modifiers on the relationship between the genotype and disease or related phenotypes will provide a more complete picture of genetic variations and the linked disease. Finally, we should note that the difference in findings might reflect true variability in the association among different populations or ethnic groups. The above reports suggest that the role of the β3-AR and UCP-1 polymorphisms is complex. Obesity and related metabolic disorders may be determined by multiple factors, such as environmental and life style components, in addition to genetic components in which many candidates genes and their interactions may be involved.

Conclusions

The present study provides evidence that the β3-AR Trp64Arg and UCP1 -3826 A > G polymorphisms are associated with TG levels in overweight/obese Chinese subjects and that the two polymorphisms are also associated with certain lipid and apolipoprotein variations, depending on BMI. However, these polymorphisms are not associated with overweight/obesity or low HDL-cholesterolemia in a Chinese population from the Chengdu area.

Methods

Subjects

For this study, blood samples were collected from 418 volunteers (242 men, 176 women, aged 53.77 ± 11.29 years) who were taking part in a routine health examination at the three hospitals of Sichuan University and Sichuan Normal University in Chengdu, China. All of these subjects were current or retired staff members of the Universities and were apparently healthy and unrelated individuals. After a 12 to 14 hour overnight fast, the blood from each individual was collected and analysed for serum concentrations of lipids, lipoproteins and apolipoproteins. BMI was calculated from height and weight measurements using the formula: BMI = body weight/(height)2 in kg/m2. According to the World Health Organization guidelines for Asians, individuals with BMI ≥ 23 kg/m2 are classified as overweight and those with BMI ≥ 25 kg/m2 are classified as obese [34]. Low HDL-cholesterolemia was defined as HDL-C < 1.04 mmol/L [35]. For the case–control study, 249 overweight/obese subjects (149 men, 100 women, aged 55.04 ± 10.00 years) with a BMI ≥23 kg/m2 and 169 normal weight (BMI < 23) subjects (93 men, 76 women, aged 53.35 ± 11.78 years) were used as the patients and controls, respectively. All of the subjects were Han Chinese living in the Chengdu area. Subjects with internal implications, such as CHD, diabetes mellitus and hypertension, were excluded. All study participants provided their informed consent, and the study was approved by the institutional review board of the hospitals of Sichuan University and Sichuan Normal University.

Quantitative analysis

Total serum cholesterol (TC) and triglycerides (TGs) were measured by enzymatic methods (kits, Zhong Sen Co., Beijing). High density lipoprotein- cholesterol (HDL-C) was determined after sodium phosphotungstate/magnesium chloride precipitation of low-density lipoprotein by polyvinyl sulfate. Serum apo A-I, apoA-II, apo B100, apo C-II, apo C-III and apo E were quantified using a radial immunodiffusion kit developed by our laboratory [36]. The serum LDL-C concentration was calculated according to the Friedewald equation [37].

DNA extraction and genotyping

Genomic DNA was isolated from 500 μl of peripheral blood according to the method of Erlich [38]. The PCRs were performed in a final volume of 25 μl containing 10% 10× PCR buffer, 2 mM MgCl2, 0.2 mM dNTPs, 0.5 U Taq DNA polymerase (MBI Fermentas) and 0.5 μM of each sense and antisense primer. We used 100 ng of DNA per PCR reaction. Genotypes for polymorphic β3-AR the Trp64Arg and UCP1 -3826 A > G polymorphisms were determined as previously described [7,18].

Statistical analysis

Comparisons of continuous variables between two or more groups were performed with an independent t-test or one-way ANOVA, respectively. Allele frequencies of the beta3-AR and UCP1 gene polymorphisms were estimated by the gene counting method. Allele and genotype frequencies were compared between cases and controls by a chi-square test. Genotypes were also assessed according to the dominant and recessive genetic model. Each genetic model comprised two groups: the combined group of variant homozygotes and heterozygotes vs wild-type homozygotes for the dominant model; and variant homozygotes vs the combined group of wild-type homozygotes and heterozygotes for the recessive model. Multiple logistic regression analysis with a stepwise forward selection procedure was performed to calculate odds ratios (OR) with obesity as a dependent variable and genotype according to the above genetic models in the presence of confounders (age and sex) as independent variables. Differences were considered statistically significant at a p-value <0.05. The statistical analyses were performed using the Statistical Package for Social Sciences (SPSS 11.0 for Windows).
  35 in total

1.  Uncoupling protein-1 mRNA expression in obese human subjects: the role of sequence variations at the uncoupling protein-1 gene locus.

Authors:  H Esterbauer; H Oberkofler; Y M Liu; D Breban; E Hell; F Krempler; W Patsch
Journal:  J Lipid Res       Date:  1998-04       Impact factor: 5.922

2.  Molecular characterization of the human beta 3-adrenergic receptor.

Authors:  L J Emorine; S Marullo; M M Briend-Sutren; G Patey; K Tate; C Delavier-Klutchko; A D Strosberg
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Polymorphisms of uncoupling protein (UCP) and beta 3 adrenoreceptor genes in obese people submitted to a low calorie diet.

Authors:  F Fumeron; I Durack-Bown; D Betoulle; A M Cassard-Doulcier; S Tuzet; F Bouillaud; J C Melchior; D Ricquier; M Apfelbaum
Journal:  Int J Obes Relat Metab Disord       Date:  1996-12

5.  Uncoupling protein 1 gene -3826 A/G polymorphism is associated with weight loss on a short-term, controlled-energy diet in young women.

Authors:  Narumi Nagai; Naoki Sakane; Kazuhiko Kotani; Taku Hamada; Kokoro Tsuzaki; Toshio Moritani
Journal:  Nutr Res       Date:  2011-04       Impact factor: 3.315

6.  The Trp64Arg polymorphism of the beta3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome.

Authors:  G N Thomas; B Tomlinson; J C Chan; R P Young; J A Critchley
Journal:  Int J Obes Relat Metab Disord       Date:  2000-05

7.  Frequency and significance of the A-->G (-3826) polymorphism in the promoter of the gene for uncoupling protein-1 with regard to metabolic parameters and adipocyte transcription factor binding in a large population-based Caucasian cohort.

Authors:  A Schäffler; K D Palitzsch; E Watzlawek; W Drobnik; H Schwer; J Schölmerich; G Schmitz
Journal:  Eur J Clin Invest       Date:  1999-09       Impact factor: 4.686

8.  A mutation of the beta 3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride.

Authors:  H Kim-Motoyama; K Yasuda; T Yamaguchi; N Yamada; T Katakura; A R Shuldiner; Y Akanuma; Y Ohashi; Y Yazaki; T Kadowaki
Journal:  Diabetologia       Date:  1997-04       Impact factor: 10.122

9.  Effects of uncoupling protein 1 and beta3-adrenergic receptor gene polymorphisms on body size and serum lipid concentrations in Japanese women.

Authors:  Hiroshi Matsushita; Takumi Kurabayashi; Masatoshi Tomita; Nozomi Kato; Kenichi Tanaka
Journal:  Maturitas       Date:  2003-05-30       Impact factor: 4.342

10.  The effects of uncoupling protein-1 genotype on lipoprotein cholesterol level in Korean obese subjects.

Authors:  Hyun Hee Oh; Kil Soo Kim; Sun Mi Choi; Hyun Sung Yang; Yoosik Yoon
Journal:  Metabolism       Date:  2004-08       Impact factor: 8.694

View more
  4 in total

1.  β2 adrenergic interaction and cardiac autonomic function: effects of aerobic training in overweight/obese individuals.

Authors:  Jhennyfer Aline Lima Rodrigues; Gustavo Duarte Ferrari; Átila Alexandre Trapé; Vitor Nolasco de Moraes; Thiago Correa Porto Gonçalves; Simone Sakagute Tavares; Arnt Erik Tjønna; Hugo Celso Dutra de Souza; Carlos Roberto Bueno Júnior
Journal:  Eur J Appl Physiol       Date:  2020-01-08       Impact factor: 3.078

2.  Cinnamomum camphora Seed Kernel Oil Improves Lipid Metabolism and Enhances β3-Adrenergic Receptor Expression in Diet-Induced Obese Rats.

Authors:  Jing Fu; Cheng Zeng; Zheling Zeng; Baogui Wang; Xuefang Wen; Ping Yu; Deming Gong
Journal:  Lipids       Date:  2016-04-11       Impact factor: 1.880

3.  Prevalence of uncoupling protein one genetic polymorphisms and their relationship with cardiovascular and metabolic health.

Authors:  Petros C Dinas; Eleni Nintou; Maria Vliora; Anna E Pravednikova; Paraskevi Sakellariou; Agata Witkowicz; Zaur M Kachaev; Victor V Kerchev; Svetlana N Larina; James Cotton; Anna Kowalska; Paraskevi Gkiata; Alexandra Bargiota; Zaruhi A Khachatryan; Anahit A Hovhannisyan; Mariya A Antonosyan; Sona Margaryan; Anna Partyka; Pawel Bogdanski; Monika Szulinska; Matylda Kregielska-Narozna; Rafał Czepczyński; Marek Ruchała; Anna Tomkiewicz; Levon Yepiskoposyan; Lidia Karabon; Yulii Shidlovskii; George S Metsios; Andreas D Flouris
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.752

4.  Stratified meta-analysis by ethnicity revealed that ADRB3 Trp64Arg polymorphism was associated with coronary artery disease in Asians, but not in Caucasians.

Authors:  Yingjian Chen; Yuanjun Liao; Shengnan Sun; Fan Lin; Rang Li; Shujin Lan; Xiaolei Zhao; Jiheng Qin; Shaoqi Rao
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.